Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by SABBOBCATon Oct 10, 2019 3:22pm

169 Views

Post# 30218773

RE:RE:RE:RE:Journal Soeculation

When did you hear it was accepted?

For The Lancet HIV specific journal it appears there is an 8 week wait for publication. The following if from the information for autheors pdf, "For research that is time sensitive, please ask about Fast Track, in which your papers will be peer-reviewed within 72 h and, if accepted, published within 8 weeks from submission".

Who knows if they got the fast track or not, but it would at least give a better timeline.

Bullboard Posts

Mastering options Greeks: Essential knowledge for informed trading